Dechra Pharmaceuticals to Acquire Invetx, Expanding its Monoclonal Antibody Portfolio for Companion Animals
Shots:
- Dechra has agreed to acquire Invetx for ~$520M on a cash-free & debt-free basis to expand its mAbs portfolio for companion animals
- The acquisition adds Invetx’s pipeline of mAbs targeting chronic diseases in cats & dogs along with candidates under development, enhancing Dechra’s expertise in atopic dermatitis & osteoarthritis plus enabling synergistic development, sales, marketing & educational efforts
- Dechra further gets access to Invetx's species-specific half-life extension platform, which increases drug activity, enabling longer treatment intervals. The technology is a part of an integrated platform comprising advanced Ab discovery, optimization, development & manufacturing of veterinary biotherapeutics
Ref: Invetx | Image: Invetx & Dechra
Related News:- Anaptys Acquires Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio Targeting Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
